DESCRIPTION: Last year, the Spanish Ministry of Health launched the Strategic Plan for Hepatitis C to ensure access to new treatments to all patients who need them. In the beginning, the estimated number of people affected by Hepatitis C was determined: 95,524 diagnosed, of which 51,964 were patients with fibrosis in F2, F3 and F4 grade, which are those who have been given priority when receiving treatment. At this moment, 52.000 patients have been treated with these drugs. Spain is the country which has more patients treated in Europe. Regarding Price and reimbursement of these drugs, the Ministry of Health and the Ministry of Finance established with regional government a specific plan of financing for ensuring that prioritized VHC patients receive new antivirals. Negotiation with pharmaceutical companies included different mechanism of financing these drugs, CAP, price for treatment and price-volume agreement. In this round table, we want to analyze the Spanish Plan and its deficiencies, different formulas used for negotiation at national and regional level and the real data obtained in registries of patients. We want also to think in the future: how to deal with new treatment and how to plan the elimination of Hepatitis C.